Doxycycline Hyclate (Quality Care Products, LLC): FDA Package Insert

Doxycycline Hyclate

DOXYCYCLINE HYCLATE- doxycycline hyclate capsule
Quality Care Products, LLC

Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline, and is available as doxycycline hyclate (doxycycline hydrochloride hemiethanolate hemihydrate) capsules and tablets for oral administration. The chemical designation of this light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline. Doxycycline has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. Doxycycline hyclate has the following structural formula:

Chemical Structure
(click image for full-size original)

(C22 H24 N2 O8 •HCl)2 •C2 H6 O•H2 O M.W. 1025.89

(C22 H24 N2 O8 •HCl)2 •C2 H6 O•H2 O M.W. 1025.89

Each capsule for oral administration contains 50 mg or 100 mg doxycycline hyclate, equivalent to 50 mg or 100 mg doxycycline (anhydrous). Inactive ingredients for capsules are: anhydrous lactose, croscarmellose sodium, D&C Red #28, FD&C Blue #1, gelatin, magnesium stearate, microcrystalline cellulose, and titanium dioxide. Each tablet for oral administration contains 100 mg doxycycline hyclate, equivalent to 100 mg doxycycline. Inactive ingredients for tablets are: anhydrous lactose, carnauba wax, croscarmellose sodium, D&C Yellow #10 aluminum lake, FD&C Red #40 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide.

CLINICAL PHARMACOLOGY

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.

Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours, decreasing to 1.45 mcg/mL at 24 hours. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min.). This percentage excretion may fall as low as 1–5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min.). Studies have shown no significant difference in serum half-life of doxycycline (range 18–22 hours) in individuals with normal and severely impaired renal function.

Hemodialysis does not alter serum half-life.

Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.

Microbiology

The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including doxycycline, have a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative organisms. Cross-resistance of these organisms to tetracyclines is common.

Gram-Negative Bacteria

  • Neisseria gonorrhoeae
  • Calymmatobacterium granulomatis
  • Haemophilus ducreyi
  • Haemophilus influenzae
  • Yersinia pestis (formerly Pasteurella pestis)
  • Francisella tularensis (formerly Pasteurella tularensis)
  • Vibrio cholerae (formerly Vibrio comma)
  • Bartonella bacilliformis
  • Brucella species

Because many strains of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended:

  • Escherichia coli
  • Klebsiella species
  • Enterobacter aerogenes
  • Shigella species
  • Acinetobacter species (formerly Mima species and Herellea species)
  • Bacteroides species

Gram-Positive Bacteria

Because many strains of the following groups of gram-positive microorganisms have been shown to be resistant to tetracycline, culture and susceptibility testing are recommended. Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible.

  • Streptococcus pyogenes
  • Streptococcus pneumoniae
  • Enterococcus group (Streptococcus faecalis and Streptococcus faecium)
  • Alpha-hemolytic streptococci (viridans group)

Other Microorganisms

  • Rickettsiae
  • Chlamydia psittaci
  • Chlamydia trachomatis
  • Mycoplasma pneumoniae
  • Ureaplasma urealyticum
  • Borrelia recurrentis
  • Treponema pallidum
  • Treponema pertenue
  • Clostridium species
  • Fusobacterium fusiforme
  • Actinomyces species
  • Bacillus anthracis
  • Propionibacterium acnes
  • Entamoeba species
  • Balantidium coli
  • Plasmodium falciparum

Doxycycline has been found to be active against the asexual erythrocytic forms of Plasmodium falciparum, but not against the gametocytes of P. falciparum. The precise mechanism of action of the drug is not known.

Susceptibility tests: Diffusion techniques: Quantitative methods that require measurement of zone diameters give the most precise estimate of the susceptibility of bacteria to antimicrobial agents. One such standard procedure1 which has been recommended for use with disks to test susceptibility of organisms to doxycycline uses the 30-mcg tetracycline-class disk or the 30-mcg doxycycline disk. Interpretation involves the correlation of the diameter obtained in the disk test with the minimum inhibitory concentration (MIC) for tetracycline or doxycycline, respectively.

Reports from the laboratory giving results of the standard single-disk susceptibility test with a 30-mcg tetracycline-class disk or the 30-mcg doxycycline disk should be interpreted according to the following criteria:

Zone Diameter (mm) Interpretation
tetracycline doxycycline
≥19 ≥16 Susceptible
15–18 13–15 Intermediate
≤14 ≤12 Resistant

A report of “Susceptible” indicates that the pathogen is likely to be inhibited by generally achievable blood levels. A report of “Intermediate” suggests that the organism would be susceptible if a high dosage is used or if the infection is confined to tissues and fluids in which high antimicrobial levels are attained. A report of “Resistant” indicates that achievable concentrations are unlikely to be inhibitory, and other therapy should be selected.

Standardized procedures require the use of laboratory control organisms. The 30-mcg tetracycline-class disk or the 30-mcg doxycycline disk should give the following zone diameters:

Organism Zone Diameter (mm)
tetracycline doxycycline
E. coli ATCC 25922 18–25 18–24
S. aureus ATCC 25923 19–28 23–29

Dilution techniques: Use a standardized dilution method2 (broth, agar, microdilution) or equivalent with tetracycline powder. The MIC values obtained should be interpreted according to the following criteria:

MIC (mcg/mL) Interpretation
≤4 Susceptible
8 Intermediate
≥16 Resistant

As with standard diffusion techniques, dilution methods require the use of laboratory control organisms. Standard tetracycline powder should provide the following MIC values:

Organism MIC (mcg/mL)
E. coli ATCC 25922 1.0–4.0
S. aureus ATCC 29213 0.25–1.0
E. faecalis ATCC 29212 8–32
P. aeruginosa ATCC 27853 8–32
Page 1 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.